Related by context. All words. (Click for frequent words.) 62 INCB# [001] 62 KNS # 62 ICA # 60 Zerenex 60 ELND# 60 bafetinib 60 alvimopan 59 teduglutide 59 tamibarotene 59 iroxanadine 59 R#/MEM # 59 IDX# 58 PEG PAL 58 tezampanel 58 TELCYTA 58 ProSavin 58 PLK1 SNALP 58 Panzem R 58 custirsen 58 TRIOLEX 58 EndoTAG TM -1 58 DP b# 58 tesetaxel 58 alvespimycin 58 methylnaltrexone 57 urocortin 2 57 RDEA# 57 OXi# 57 nonclinical studies 57 tafamidis 57 Phase IIb clinical 57 Asentar 57 AeroLEF 57 dimebon 57 CEQ# 57 Dacogen injection 57 Panzem 57 lomitapide 57 NGX# 57 MGCD# [001] 57 Alzhemed TM 57 ruxolitinib 57 Insegia 57 glufosfamide 57 Phenoptin 57 talactoferrin 57 PBT2 56 Azixa 56 PrevOnco ™ 56 PEG SN# 56 PS# [001] 56 systemically administered 56 NTx TM -# 56 elotuzumab 56 Fx #A 56 veltuzumab 56 preclinical 56 ReN# 56 Androxal TM 56 GATTEX 56 Arimoclomol 56 SILENOR TM 56 MAXY alpha 56 lesinurad 56 oral prodrug 56 PD LID 56 omecamtiv mecarbil 56 eniluracil 56 tanespimycin 56 picoplatin 56 PRX # 56 Amigal 56 tezampanel NGX# 56 vilazodone 55 APOPTONE 55 pralatrexate 55 Phenserine 55 Archexin 55 Prestara 55 L MTP PE 55 CORT # 55 PRT# 55 Fibrillex TM 55 Triolex 55 CDP# 55 GGF2 55 phase IIb clinical 55 HGS ETR1 55 Behcet uveitis 55 confirmatory Phase III 55 Azedra TM 55 HspE7 55 favorable pharmacokinetic profile 55 AzaSite Plus 55 Cintredekin Besudotox 55 AVE# 55 investigational drug 55 TELINTRA 55 SonoLysis 55 elacytarabine 55 MEK inhibitor 55 GLP toxicology studies 55 IMiDs 55 Proxinium TM 55 forodesine 55 entinostat 55 BAY #-# 55 Phase Ib study 54 Chrysalin 54 Desmoteplase 54 Valortim 54 opioid induced bowel dysfunction 54 Acapodene 54 PREOS 54 Neo Urinary Conduit 54 TBC# 54 ASONEP 54 Nasulin 54 MEK inhibitor RDEA# 54 #D#C# 54 Phase IIb 54 Tamibarotene 54 Azedra 54 CK # 54 Relivar 54 epratuzumab 54 cannabinor 54 Phase IIa trials 54 PF # [001] 54 ridaforolimus 54 Amplimexon 54 NEUMUNE 54 ELACYT 54 refractory gout 54 subcutaneous formulation 54 CINTREDEKIN BESUDOTOX 54 Zalbin 54 metaglidasen 54 ISIS # 54 Q#IR 54 MAGE A3 ASCI 54 Troxatyl 54 dirucotide 54 Arikace 54 Bicifadine 54 TYZEKA 54 Aurexis 54 alagebrium 54 ATL# [001] 54 IV APAP 54 romiplostim 54 Allovectin 7 ® 54 TKM ApoB 54 axitinib 53 AZILECT R 53 dacetuzumab 53 PEG Interferon lambda 53 Symadex 53 lintuzumab SGN 53 TOCOSOL Paclitaxel 53 squalamine 53 TRISENOX 53 DR Cysteamine 53 Phase 2a 53 SNT MC# 53 Phase III clinical 53 Apoptone 53 registrational 53 HuLuc# 53 Excellarate 53 ZYBRESTAT 53 LEP ETU 53 CCX# 53 bardoxolone 53 obatoclax 53 NPSP# 53 AQ4N 53 ALKS 53 Posiphen 53 riociguat 53 daclizumab 53 ularitide 53 tremelimumab 53 UVIDEM 53 bicifadine 53 HuMax EGFr 53 RLY# 53 Cethrin 53 XP# XP# 53 refractory chronic lymphocytic 53 oral methylnaltrexone 53 BYDUREON 53 ALN VSP 53 interferon gamma 1b 53 ISTODAX 53 faropenem 53 refractory APL 53 Viprinex 53 otelixizumab 53 Menerba 53 Sym# 53 Onalta 53 anticancer compound 53 #ME# 53 QNEXA 53 Zingo TM 53 Proellex TM 53 multiple ascending dose 53 Cloretazine R VNP#M 53 investigational monoclonal antibody 53 ecallantide 53 Zemiva TM 53 ganetespib 53 CORLUX 53 leading oral taxane 53 generation purine nucleoside 53 Cannabinor 53 orBec R 53 vosaroxin 53 Phase 1b 53 Sulonex 53 DAVANAT R 53 ostarine 53 Trofex 53 Cloretazine 53 Traficet EN 53 Cleviprex TM clevidipine 53 XmAb# 53 FOLOTYN 53 PEGPH# 53 Phase 2a trial 53 thymalfasin 53 AEOL # 53 dyskinesia PD LID 53 rNAPc2 53 Anthim 53 AZD# 53 BrachySil 52 Ostarine 52 Solazed 52 IPLEX 52 Memryte 52 Aviptadil 52 EFAPROXYN 52 FRDA 52 MAP# 52 Exherin TM 52 ADX# 52 Genz # 52 HGS ETR1 mapatumumab 52 LymphoStat B 52 novel VDA molecule 52 PXD# 52 AZILECT ® 52 hGH CTP 52 Aerosurf 52 TRO# 52 Serdaxin 52 XL# [003] 52 imetelstat 52 teplizumab 52 IMA# 52 midstage trials 52 EOquin TM 52 darapladib 52 MAXY G# 52 Azilect ® 52 eltrombopag 52 oral FTY# 52 phase IIa clinical 52 ospemifene 52 OncoVEX GM CSF 52 JAK inhibitor 52 PSMA ADC 52 HGS ETR2 52 BLA submission 52 Neo Kidney Augment 52 Allovectin 7 R 52 SRT# [003] 52 Marqibo 52 RGB # 52 Linjeta TM 52 Genasense R oblimersen 52 lurasidone 52 HuMax CD# 52 Riquent 52 dosing cohort 52 FOLOTYN ® 52 EVIZON TM squalamine lactate 52 MOZOBIL 52 XL# anticancer compounds 52 Phase Ib clinical trials 52 AVN# [001] 52 Orathecin 52 preclinical pharmacokinetic 52 dexanabinol 52 CA4P 52 Clonicel 52 drug GAP #B# 52 orBec 52 LibiGel ® 52 sodium Injection 52 Protexia R 52 Zenvia ™ 52 ocrelizumab 52 Restanza 52 diabetic neuropathic pain 52 Neuradiab 52 Solazed TM 52 Phase 2b study 52 sorafenib tablets 52 CoFactor 52 candidate Zenvia 52 Anturol ® 52 ApoB SNALP 52 Exelixis compounds 52 danoprevir 52 Panzem R NCD 52 oral ridaforolimus 52 MyVax R 52 huC# DM4 52 Synavive 52 lubiprostone 52 ganaxolone 52 Genasense ® oblimersen 52 PROMACTA 52 PNP inhibitor 52 valopicitabine 52 GAP #B# 52 Stimuvax R 52 tivozanib 52 ocular formulation 52 Huntexil 52 oral gallium 52 voreloxin 52 chemotherapy induced neutropenia 52 Phase 2b clinical 52 torezolid phosphate 52 Cogane 52 IIa trial 52 histone deacetylase inhibitor 52 ONTAK 52 PHX# 52 AEG# 52 Actilon 52 huN# DM1 52 ADVEXIN 51 Phase III clinical trials 51 forodesine HCl 51 Laquinimod 51 ALN TTR# 51 mGluR2 NAM 51 Icatibant 51 eprodisate KIACTA TM 51 Zelrix 51 Plicera 51 HQK 51 PROPEL trial 51 CIMZIA TM 51 blinatumomab 51 HCV protease inhibitor 51 selective androgen receptor modulator 51 Entereg R 51 PDE4 inhibitor 51 MDV# 51 Mylotarg 51 Oral NKTR 51 CB2 selective receptor agonist 51 GED aPC 51 MYDICAR ® 51 EOquin 51 ANAVEX #-# [003] 51 Glybera 51 TOCOSOL Camptothecin 51 ozarelix 51 Phase 2b trial 51 NKTR 51 elagolix 51 RhuDex ® 51 Soliris eculizumab 51 Acute Radiation Syndrome ARS 51 Parkinson disease levodopa induced 51 midstage clinical 51 ONCONASE R 51 Phase Ib 51 synthetic retinoid 51 PhosLo 51 Phase IIa clinical 51 DXL# 51 AMPAKINE R 51 Gabapentin GR 51 preclinical studies 51 NP2 Enkephalin 51 hormone refractory prostate cancer 51 MAXY VII 51 Tyrima 51 refractory Hodgkin lymphoma 51 Phase IIb trial 51 Junovan TM 51 IND submission 51 L DOS# 51 brivaracetam 51 Trizytek 51 sargramostim 51 Cardio Vascu Grow 51 CGEN # 51 volociximab 51 Urocortin 2 51 Corlux 51 metastatic castration resistant 51 drug ISA# 51 eculizumab 51 Phase 1a clinical 51 DAVANAT 51 AeroLEF TM 51 Anturol 51 Preclinical studies 51 BNC# 51 Phase IIa trial 51 tiapamil 51 Phase IIa 51 Soliris TM eculizumab 51 silodosin 51 Phase IIa clinical trials 51 Combidex 51 Phase IIB 51 IMGN# 51 oral deforolimus 51 bardoxolone methyl 51 CCR5 mAb 51 Surfaxin LS 51 YONDELIS 51 mifamurtide 51 HCV nucleotide polymerase inhibitor 51 IRX 2 51 GATTEX ® 51 Bezielle 51 lixivaptan 51 Ceflatonin 51 TACI Ig 51 Canvaxin 51 ZOLINZA 51 phase 2a 51 RG# [001] 51 nalbuphine ER 51 Cladribine Tablets 51 HepeX B 51 TH# [003] 51 Advexin 51 velafermin 51 darinaparsin 51 targeted radiotherapeutic 51 ALN PCS 51 mitogen activated ERK kinase 51 docetaxel chemotherapy 51 Onalta ™ 51 Targretin 51 Exalgo TM 51 Phase IIb trials 51 initiate Phase 1b 51 Shigamabs R 51 docetaxel Taxotere R 51 pomalidomide 51 Mepact 51 satraplatin 51 deforolimus 51 anticancer agent 51 registrational trial 51 clinical trials 51 Virulizin R 51 AP# [003] 51 BLA filing 51 relapsed multiple myeloma 51 cinacalcet HCl 51 oral calcitonin 51 tesmilifene 51 Aegerion 51 ALN TTR 51 perampanel 51 rindopepimut 51 ulimorelin 50 ataluren 50 CORLUX CORT # 50 pafuramidine 50 enzastaurin 50 Phase 2a clinical trials 50 amrubicin 50 Ketotransdel 50 subcutaneous RELISTOR 50 sapacitabine 50 ILUVIEN ® 50 pharmacological chaperone 50 tecarfarin 50 OPAXIO 50 SUVN 50 lucinactant 50 carfilzomib 50 EP #R 50 gemcitabine Gemzar ® 50 personalized immunotherapy 50 IAP inhibitor 50 celgosivir 50 Dapagliflozin 50 oxymorphone ER 50 nimotuzumab 50 BCX# 50 eprotirome 50 SparVax TM 50 Chemophase 50 Nicole Onetto MD 50 HGS# 50 mapatumumab 50 IL# PE#QQR 50 Neurodex 50 GALNS 50 Phase 2a clinical 50 lintuzumab 50 Jevtana 50 Urokinase 50 Cinryze ™ 50 bavituximab 50 dextromethorphan quinidine 50 vascular disrupting agent 50 ponatinib 50 Fodosine 50 triphendiol 50 TLK# 50 APD# 50 IND enabling 50 BrachySil TM 50 LEVADEX TM 50 intranasal formulation 50 SAR# [004] 50 Octreolin 50 midstage clinical trials 50 Phase IIb clinical trials 50 iSONEP 50 ZADAXIN ® 50 ambrisentan 50 Zybrestat 50 ImmunoVEX HSV2 50 Diamyd ® 50 ORE# 50 Phase #/#a trial 50 oncology indications 50 romidepsin 50 post operative ileus 50 AA amyloidosis 50 Prodarsan ® 50 Triapine R 50 RAPTIVA 50 Civacir 50 davunetide intranasal AL 50 trastuzumab DM1 T DM1 50 ARYx 50 castrate resistant prostate cancer 50 maribavir 50 oral formulation 50 Rhucin ® 50 incyclinide 50 Revimmune 50 Hsp# inhibitor 50 Ocrelizumab 50 Tavocept 50 depsipeptide 50 Tovaxin 50 telaprevir VX 50 HuMax CD4 50 perifosine 50 BEMA Buprenorphine 50 opioid bowel dysfunction 50 Phase Ib clinical 50 Pimavanserin 50 Nexavar ® 50 vidofludimus 50 AGGRASTAT ® 50 virus HCV protease inhibitor 50 Phase 1b trial 50 mertansine 50 oxypurinol 50 MBP# [001] 50 Cetrorelix 50 anti EGFR antibody 50 ongoing Phase 1b 50 CYT# potent vascular disrupting 50 Anavex #-# 50 KRN# 50 Vilazodone 50 Veronate 50 Stedivaze 50 trans retinoic acid ATRA 50 MEK inhibitors 50 Plenaxis TM 50 paclitaxel Taxol ® 50 HCV protease inhibitors 50 neuroprotective properties 50 pain palliation 50 R#/MEM 50 TKM PLK1 50 Virulizin ® 50 TREANDA 50 lumiliximab 50 pseudobulbar affect PBA 50 adipiplon 50 Amigal TM 50 atacicept 50 orally bioavailable 50 SinuNase TM 50 HCD# [002] 50 TRANSDUR Sufentanil 50 Annamycin 50 Cinryze TM 50 CR# vcMMAE 50 Naglazyme 50 GTC recombinant human 50 L BLP# 50 Genasense 50 NEBIDO 50 thetreatment 50 PRX# 50 tolevamer 50 inhaled liposomal ciprofloxacin 50 neratinib 50 oral taxane 50 Amrubicin 50 ixabepilone 50 GRN#L 50 Onconase 50 Linjeta ™ 50 Phase #b/#a 50 Valortim ® 50 Alpharadin 50 sulodexide 50 Onrigin 50 EVIZON TM 50 ibudilast 49 torsemide ER 49 6R BH4 49 evaluating tivozanib 49 Ophena TM 49 betrixaban 49 BENLYSTA ® 49 GSK # 49 XL# XL# XL# XL# 49 AAG geldanamycin analog 49 forodesine hydrochloride 49 novel anticancer 49 Actimmune ® 49 lorvotuzumab mertansine 49 Personalized Immunotherapy 49 liposomal formulation 49 vorinostat 49 Neo Kidney Augment ™ 49 XIFAXAN R 49 liprotamase 49 Golimumab 49 PROVENGE sipuleucel T 49 Safinamide 49 Xanafide 49 rhThrombin 49 prostone 49 Preclinical studies suggest 49 pitavastatin 49 PSN# [002] 49 PNT# 49 elesclomol 49 docetaxel Taxotere 49 seliciclib CYC# 49 ImaRx 49 dacetuzumab SGN 49 LymphoStat B TM 49 Alocrest 49 dose cohorts 49 epothilone 49 hypoparathyroidism 49 GRN# 49 Voraxaze 49 histone deacetylase HDAC inhibitor 49 Fludara 49 Zerenex ™ 49 clinical trial 49 Abraxane 49 AEGR 49 PDE# inhibitors 49 low dose cytarabine 49 Lisofylline LSF 49 CRMD# 49 INCB# [002] 49 Protectan CBLB# 49 oritavancin 49 pertuzumab 49 Xcytrin R 49 Cellegesic 49 radiotherapeutic 49 PI3K/Akt pathway inhibitor 49 Entereg TM 49 injectable formulation 49 posaconazole 49 LHRH antagonist 49 decitabine 49 retigabine 49 Tarceva TM 49 oral bioavailability 49 Pruvel 49 ProLindac 49 febuxostat 49 compound INCB# 49 investigational 49 StemEx R 49 ATPace TM 49 ENMD # 49 Besivance 49 XYOTAX 49 Vicinium TM 49 SARMs 49 Urocidin TM 49 pharmacodynamic properties 49 OvaRex ® MAb 49 clinical pharmacology studies 49 pivotal Phase III 49 Cimzia ® certolizumab pegol 49 ATL# [002] 49 granulated mesalamine 49 radiation sensitizer 49 IV Busulfex 49 GENR 49 Onco TCS 49 FROVA 49 allosteric modulator NAM 49 Ceflatonin ® 49 intravenous acetaminophen 49 bevirimat 49 Protexia ® 49 mipomersen 49 BRAF V# mutation 49 GLPG# 49 Phase #b/#a clinical 49 Generx ™ 49 temsirolimus 49 docetaxel Taxotere ® 49 mGluR5 negative 49 phase IIb 49 Phase III confirmatory 49 Bortezomib 49 lapatinib Tykerb 49 RAPAFLO 49 Spiegelmer ® 49 arsenic trioxide ATO 49 lenalidomide Revlimid R 49 TRISENOX ® 49 rBChE 49 Zavesca r 49 CBLC# 49 pharmacodynamic 49 DOS# 49 clofarabine 49 Azedra ™ 49 PrevOnco 49 Myocet 49 Lixivaptan 49 relapsing remitting multiple sclerosis 49 Clolar ® 49 CBLB# 49 Zelapar 49 PEG INTRON 49 Debio 49 Folotyn 49 POSIDUR 49 alogliptin 49 Junovan 49 MONOVISC 49 ThermoDox R 49 CIMZIA ™ 49 FavId 49 pharmacodynamic PD 49 hypoxia activated prodrug 49 LentiVector technology 49 orally administered inhibitor 49 Staccato loxapine 49 sodium thiosulfate STS 49 romidepsin novel 49 Cimzia ® 49 PCK# 49 BRIM2 49 infusional 5-FU/LV 49 Microcyn Technology 49 phase IIa 49 Campath ® 49 fenofibric acid 49 Mozobil 49 VEGF Trap 49 NexACT 49 investigational compounds 49 preclinically 49 CytRx 49 Phase Ia 49 proteasome inhibitor 49 Emezine 49 refractory PTCL 49 Avicena 49 linaclotide 48 rilonacept 48 BENLYSTA 48 MGd 48 dermal patch 48 prGCD 48 cystinosis patients 48 relapsed leukemia 48 RSD# oral 48 Marketing Authorization Application 48 OHR/AVR# 48 CD# CEA 48 Mr. Bentsur 48 ONCONASE 48 rxRNA 48 CIP TRAMADOL ER 48 SURFAXIN 48 XL# XL# 48 dose escalation study 48 aflibercept 48 Cimzia TM 48 Hsp# inhibition 48 molecular chaperone 48 bremelanotide 48 Marqibo TM 48 Torisel 48 vandetanib 48 nitazoxanide 48 clevudine 48 FOLFOX chemotherapy 48 ARIKACE ™ 48 rALLy trial 48 investigational humanized monoclonal antibody 48 therapeutic monoclonal antibody 48 zanolimumab 48 uric acid lowering 48 Mipomersen 48 molecular chaperone regulation 48 ZEVALIN ® 48 dalbavancin 48 CK # novel 48 NASDAQ OSIR 48 velaglucerase alfa 48 PDX pralatrexate 48 zileuton 48 doxorubicin HCl liposome injection 48 TYKERB 48 GRNCM1 48 COPREXA 48 IMC #B 48 preclinical toxicology 48 visilizumab 48 UltiMAb 48 adecatumumab 48 PRTX 48 class mGluR5 inhibitor 48 Aurora kinase inhibitor 48 faropenem medoxomil 48 bazedoxifene 48 Cloretazine ® 48 pharmacokinetic 48 Bronchitol 48 rufinamide 48 omacetaxine mepesuccinate 48 Ceplene/IL-2 48 Vion Pharmaceuticals 48 AcelRx 48 Bendavia 48 Tectin TM 48 Homspera 48 Gemzar ® 48 OMNARIS HFA 48 MEPACT 48 carcinogenicity study 48 TKM Ebola 48 Phase IIIb clinical 48 Celladon Corporation 48 belinostat 48 inhaled formulation 48 JAK1 48 Omacetaxine 48 Locteron ® 48 elvucitabine 48 Zenvia TM 48 CUDC 48 Phase 2b 48 OvaRex R 48 ONGLYZA ™ 48 refractory acute myeloid 48 gemcitabine chemotherapy 48 Panzem NCD 48 orally dosed 48 Intravenous CP 48 GATTEX ™ 48 phase IIb trial 48 generation Hsp# inhibitor 48 generation URAT1 inhibitor 48 Æterna Zentaris 48 pradefovir 48 pharmacokinetic studies 48 TRAIL receptor antibodies 48 Tarvacin TM 48 masitinib 48 investigational antiplatelet agent 48 PREOS R 48 multicenter Phase II 48 TORISEL 48 ofatumumab 48 MoxDuo IR 48 Imprime PGG 48 investigational compound 48 Arcalyst 48 DAVANAT ® 48 Inc. NASDAQ AVNR 48 DPX Survivac 48 octreotide implant 48 candidate XP# 48 Frova ® 48 Aplidin 48 PRECISE trial 48 nicotinic alpha 7 48 multiple myeloma MM 48 BiTE antibody 48 carbidopa levodopa 48 Vandetanib 48 EGRIFTA TM 48 non metastatic osteosarcoma 48 Iluvien ® 48 BCR ABL inhibitor 48 dose escalation Phase 48 Genasense ® 48 FOLFOX6 chemotherapy regimen 48 ASA# 48 Serostim ® 48 Excellagen 48 investigational hepatitis B 48 VitiGam 48 EnzymeRx 48 Locteron 48 CD# antibody [001] 48 Phase III 48 SinuNase ™ 48 XL# XL# XL# 48 teriflunomide 48 Rhucin 48 ATPace 48 BEMA TM Fentanyl 48 REMOXY R 48 Genitope Corporation 48 severe gastroparesis 48 rALLy clinical trial 48 placebo controlled Phase 48 active comparator 48 SCH # 48 motexafin gadolinium Injection 48 cilengitide 48 palonosetron 48 New Drug IND 48 ADVEXIN p# therapy 47 Nabi HB Intravenous 47 CG# [003] 47 hoFH 47 sunitinib malate 47 systemic ALCL 47 calcineurin inhibitors 47 cutaneous T 47 Friedreich Ataxia FRDA 47 Certolizumab pegol 47 TREDAPTIVE 47 darinaparsin ZIO 47 OncoVEX 47 Biologics License Application 47 Perforomist ™ Inhalation Solution 47 Harbor BioSciences 47 Neulasta ® 47 nab paclitaxel 47 Evoltra ® 47 ATryn ® 47 Tanespimycin 47 AZX# 47 indibulin 47 preclinical models 47 RELISTOR ® 47 IBS C 47 MAA submission 47 Zolinza 47 Ceplene 47 APTIVUS 47 Alvesco R 47 Acetavance TM 47 budiodarone 47 Zavesca ® 47 Dacogen 47 Evoltra 47 intravenous ghrelin agonist 47 Augment TM 47 ATL/TV# 47 opioid induced constipation 47 phase Ib